13th Edition

Innovinc
DEDICATED TO YOUR SUCCESS

Global Insight Conference on

BREAST CANCER

GICBC-2026

Jun 29 - 30, 2026

Rome, Italy (Belstay Roma Hotel)

(Hybrid Event)

Website URL: https://gicbc.org/

Email: breastcancer@innovinc.org

Phone: +1-408-465-0048

WhatsApp: +1-408-352-1010

Meeting Hall: PARIOLI 2

Registrations Open (08:00-09:30)

Opening Ceremony (09:30-09:45)

Moderator: Kosmia Loizidou, *University of Cyprus, Cyprus*

Keynote Talks

09:45-10:15	**Title: Impact of body mass index on the surgical outcomes and delayed adjuvant treatment in patients undergoing therapeutic mammoplasty for breast cancer** **Maged Hussien,** *Norfolk and Norwich University hospital, United Kingdom*
10:15-10:45	**Title: Medical research ethics with a focus on breast cancer** **Jukka H. Meurman,** *University of Helsinki, Finland*
10:45-11:15	**Title: Translational Bioinformatics Resources and AI Solutions for Cancer Research** **Trupti Joshi,** *Marshall University, USA*

Group Photo

11:15-11:30 - Refreshment Break @ Foyer

SCIENTIFIC SESSION-I

Session Chair:

Hanna Romanska-Knight, *Medical University of Lodz, Poland*

Plenary Talk

11:30-11:55	**Title: A novel HER2 protein identification methodology in breast cancer cells using Raman spectroscopy and raman imaging: an analytical validation study** **Halina Abramczyk,** *Lodz University of Technology, Poland*
11:55-12:20	**Title: Fraction B Preparation from Catfish Skin is a Good Candidate for treating Breast Cancer Without the Use of Surgery, Radiation or Chemo Treatment and for Healing Wounds Cosmetically After Breast Cancer Surgery** **Jassim M. H. AlMohammad Ali,** *Abdullah AlSalem University, Kuwait*
12:20-12:40	**Title: Natural looking breast after primary reconstruction using inferior dermal flap as internal bra and submuscular silicone implant** **Jasmina Gjorgievska Pavlovska,** *University Clinic of Plastic and reconstructive surgery - North Macedonia*
12:40-13:00	**Title: Shaping the Future: AI-Driven Solutions in Breast Reconstruction** **Edward Ray,** *Cedars-Sinai Medical Center, USA*

Networking & Panel Discussion

13:00-13:50 Lunch Break @ Restaurant

SCIENTIFIC SESSION-II

Session Chairs:

Halina Abramczyk, *Lodz University of Technology, Poland &*

Columba De La Parra, *Lehman College- City University of New York, USA*

13:50-14:10	**Title: Systems-Level Reprogramming of Breast Cancer by the Traditional Chinese Medicine Formula T33: Integrating Epigenetic Regulation, Autophagy, and Tumor Evolution** **YuTe Liu,** *Chung Shan Medical University, Taiwan*
14:10-14:30	**Title: PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence** **Haiying Zhan,** *Yale University, USA*
14:30-14:50	**Title: RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases** **Hui-Wen Lo,** *Texas A&M University Naresh K. Vashisht College of Medine, USA*
14:50-15:10	**Title: Mechanisms of Action of FDA-Approved Endocrine Therapies for ER-Positive Breast Cancer** **Kiven Erique Lukong,** *University of Saskatchewan, Canada*
15:10-15:30	**Title: DCIS-associated myoepithelial cells create a pro-tumorigenic microenvironment through up-regulation of integrin αvβ6** **J Louise Jones,** *Queen Mary University of London, United Kingdom*
15:30-15:50	**Title: FGF/FGFR-Signalling in triple-positive breast cancer: molecular subtyping in aid of disease prognostication** **Hanna Romanska-Knight,** *Medical University of Lodz, Poland*

15:50-16:00 Refreshment Break	
16:00-16:20	**Title:Proteomics Approaches in Discovery of Potential Enzymatic Biomarkers for Early Diagnosis of Breast Cancer** **Zoran Minic,** *University of Ottawa, Canada*
16:20-16:40	**Title: Targeting Tumor-Associated Hydroxyapatite to Disrupt Tumor Metabolism: A Novel Therapeutic Strategy for Breast Cancer Using Nanodrugs** **Mohammed Noor Tantawy,** *Vanderbilt University Medical Center, USA*
16:40-17:00	**Title: Identification and Therapeutic Targeting of Tumor-initiating Cells in Triple-negative Breast Cancer (TNBC)** **Michael T. Lewis,** *Baylor College of Medicine, USA*
Networking & Panel Discussion	
Day-1 Concludes	

Meeting Hall: PARIOLI 2

Moderator:

Hui-Wen Lo, *Texas A&M University Naresh K. Vashisht College of Medine, USA*

KEYNOTE TALKS	
09:30-10:00	**Title: Breast Cancer Diagnosis using Subtraction of Temporally Sequential Digital Mammograms** **Kosmia Loizidou,** *University of Cyprus, Cyprus*
10:00-10:30	**Title: Crosstalk Between Metabolism and Translation in Highly Metastatic Triple-Negative Breast Cancer (TNBC)** **Columba De La Parra,** *Lehman College- City University of New York, USA*
10:30-11:00	**Title: The Luminous Pro Series, Pink Luminous Breast, an LED based technology utilizing patented red light wavelengths between 640 to 800 nanometers, has demonstrated comparable sensitivity and specificity to mammography in detecting breast abnormalities** **Marylin R Dans,** *U R Luminous, USA*
11:00-11:15 - Refreshment Break @ Foyer	

SCIENTIFIC SESSION-III

Session Chairs:

Amy S Yee, *Tufts University School of Medicine, New Orleans (LSUHSC-NO), USA*

Mohammed Musa Yahya Alzahrani, *Imam Mohammad Bin Saud Islamic University, Saudi Arabia*

11:15-11:35	**Title: Caspase Activation, Upregulation of Bax and P53, Downregulation of Bcl-2 and Enhanced Generation of Reactive Oxygen Species Mediate the Anti-proliferative and Anti-migratory Activity of Mefenamic Acid in Breast Cancer Cellss** **Mohammed Musa Yahya Alzahrani,** *Imam Mohammad Bin Saud Islamic University, Saudi Arabia*
11:35-11:55	**Title: Pain and Lymphedema Characteristics of Women with Breast Cancer-Related Lymphedema with and without Type 2 Diabetes Mellitus** **Esra Uzelpasaci,** *University of Health Sciences, Turkey*
11:55-12:15	**Title: CHA1: An Epigenetics-Plus Combinatorial Therapy That Enables Immune Checkpoint Susceptibility with Epigenetic Disruption** **Amy S Yee,** *Tufts University School of Medicine, New Orleans (LSUH-SC-NO), USA*
12:15-12:35	**Title: Deep learning and transfer learning identify breast cancer survival subtypes from single-cell imaging data** **Lana Garmire,** *University of Alabama at Birmingham, USA*
12:35-12:55	**Title: Iron Status Across the Menopausal Transition: A Dual Mechanism Driving Breast Cancer Incidence and Recurrence** **Makfire Ajeti,** *Anglia Ruskin University, Turkey*

12:55 -1:55 Lunch @ Restaurant

Conference Concludes

MARYLIN DANS CEO/ FOUNDER

SILKPRO USA, POWER AESTHETIC GROUP, PINK LUMINOUS ADVOCACY PROJECT and CO-CREATOR OF THE PINK LUMINOUS BREAST DEVICE

Marylin Dans, a remarkable entrepreneur and visionary advocate committed to revolutionizing global breast health and well-being, is the driving force behind transformative initiatives such as SilkPro USA, Power Aesthetic Group, Pink Luminous Advocacy Project, and the groundbreaking Pink Luminous Breast Device. With an unwavering dedication to harnessing cutting-edge technology, Marylin is spearheading an unprecedented movement towards a healthier future.

At a pivotal moment in her life, Marylin's path took an unexpected turn when, at the young age of 17, she discovered a lump in her breast. This deeply personal experience ignited a lifelong mission to empower individuals with the tools and knowledge to take control of their health.

Central to her mission is the Pink Luminous Advocacy Project, a non-profit organization. Through pioneering research, education, and essential medical support, Marylin and her team are championing early detection and proactive health management.

This dedication has also led to the creation of the innovative Breast Awareness App, this groundbreaking app serves as a guide, educating, and empowering individuals to establish an awareness routine within the comfort of their own homes, fostering a culture of proactive health management.

Another shining example of Marylin's commitment is the Light'em Up Initiative, a pioneering collaboration between Pink Luminous Advocacy Project and SilkPro USA to combat health inequities. The program aims to fund medical mission trips, extending enhanced breast health education and monitoring to underserved communities worldwide. Generous grants under the Light'em Up Program facilitate the acquisition and deployment of the Pink Luminous Breast Device, a revolutionary technology that plays a pivotal role in breast health monitoring.

The Pink Luminous Breast Device, is the world's first direct-to-consumer breast familiarity tool, enabling individuals to establish a visual baseline for optimal breast health management.

Harnessing the power of patented Red LED Technology, the Pink Luminous Breast Device illuminates the soft tissue and venous flow of the breast. Its ability to detect dark or shadowed areas serves as a crucial alert for potential abnormalities, prompting timely medical evaluation and potentially saving lives through early intervention.

Scientifically validated through a rigorous IRB double-blind study, the Pink Luminous Breast Device has proven to be a true game-changer. It boasts heightened sensitivity, specificity, and dense findings compared to the traditional gold standard of mammography. This remarkable achievement signifies a paradigm shift in at-home breast wellness monitoring, offering a newfound sense of empowerment and control.

In a world where breast cancer remains a significant global concern, with many cases going undetected until later stages, Marylin's mission is more crucial than ever. With the Pink Luminous Breast Device at the forefront, her efforts are paving the way for a future where proactive health management becomes the norm.

Beyond her entrepreneurial pursuits, Marylin Dans is a philanthropist with a heart of gold. Her involvement with esteemed organizations such as the American Cancer Society, Project CURA, and the Nicklaus Children's Hospital Foundation, where she holds a revered position in the Diamond Society, reflects her unwavering commitment to making a positive impact. Moreover, Marylin's dedication has taken her to the frontlines of change. She has personally led medical missions to Haiti and most recently collaborated with Angels for Humanity in San Salvador, embodying her belief in the power of hands-on service to transform communities and lives.

Recognized by both national and international media outlets, Marylin's journey, featured on platforms such as Fox, Telemundo, Univision, and prominent magazines, serves as a testament to her exceptional entrepreneurial acumen in the fields of health and technology.

As Marylin's story continues to unfold, one thing is clear: the Pink Luminous Breast Device stands as a groundbreaking tool that is redefining breast health monitoring and early detection. With Marylin Dans at the helm, her unwavering dedication to universal health and breast health awareness is reshaping the way we approach proactive well-being. Join her transformative journey and embrace an awareness lifestyle today – because early detection truly saves lives.

SILKPRO USA

Virtual Session

13th Edition of Global Insight Conference on

BREAST CANCER

Jun 29 - 30, 2026 at Rome, Italy *(Hybrid Event)*

Join Zoom Meeting

10:40-11:00	**Title: Breast Cancer Survivorship: Lived Experiences of Challenges and Accessing Support for Psychological Distress** **Syeda Zakia Hossain,** *University of Sydney, Australia*
11:00-11:20	**Title: Knowledge Mapping of Global Trends in DNA Damage Repair-related Breast Cancer Research: A Bibliometric Study** **Yajing Huang,** *Second Affiliated Hospital, School of Medicine, Zhejiang University, China*
11:20-11:40	**Title: Association between adjuvant chemotherapy and outcomes after resection of locoregional recurrence in hormone receptor–positive HER2-negative breast cancer: a multi-institutional retrospective study** **Yukinori Ozaki,** *Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan*
11:40-12:00	**Title: Real time App Deployment : Analysis of Image for Breast Cancer Detection using Feature-Rich Deep Learning Architecture** **Pinki Roy,** *National Institute of Technology Silchar, India*
12:00-12:20	**Title: Mutation analysis in investigating the status of genes associated with homologous recombinant repair in hormone receptor-positive breast cancer** **Tekincan Cagrı Aktas,** *Ege University Faculty of Medicine, Turkey*
12:20-12:40	**Title: Dissecting Notch-driven EMT programs at single-cell resolution in breast cancer** **Magdalena Orzechowska,** *Medical University of Lodz, Poland*

12:40-13:00	**Title: Understanding Chemo-Brain: Is Exercise a Pathway to Cognitive Health in Breast Cancer Survivorship?** **Ozgu Inal Ozun,** *University of Health Sciences, Turkey*
13:00-13:20	**Title: Immunomodulating and antiproliferative effects of novel N-chalconyl im-idazolidones in breast cancer models** **Atziri Corin Chavez Alvarez,** *Université Clermont-Auvergne, France*
13:20-13:30	**Title: Expression of PD-L1, IRF1 and CD8 T Lymphocyte Infiltration in a Primary Subset of Breast Cancer Patients in Sudan** **Shahenaz Shaban Salih Mohamed Nour,** *Sudan University of Sciences and Technology, UAE*
13:30-13:50	**Title: HER2 amplification by next-generation sequencing to identify her2-positive invasive breast cancer with negative her2 immunohistochemistry** **Ying S. Zou,** *The Johns Hopkins University, USA*
13:50-14:10	**Title: Relationship between diagnostic characteristics, lifestyle habits and breast cancer subtypes in women** **Fernanda Cristina Marin,** *Escola de Enfermagem da Universidade de São Paulo, Brazil*
14:10-14:30	**Title: The Prognostic Utility of Perioperative Blood-based Liquid Biopsy in Patients with Non-metastatic Breast Cancer** **Fara Hassan,** *Cork University Hospital, Ireland*
14:30-14:50	**Title: The Causal Effect of 24-hour Activity Patterns in Adulthood on Breast Cancer Risk Among Polish Migrant Women in US** **Azam Najaf Kouchak,** *Michigan State University, USA*
14:50-15:10	**Title: A Case of Grade II Breast Mucinous Carcinoma Progression from Ductal Carcinoma in Situ** **Clara Straus,** *St. John's Episcopal Hospital, USA*

15:10-15:30	**Title: Dose-Dependent Mitochondrial Reprogramming by Biguanides Antagonistically Regulates c-Src–Driven Tumor Progression** **Benny Abraham Kaipparettu,** *Baylor College of Medicine, USA*
15:30-15:50	**Title: Beyond Cancer: BRCA as Guardians of Cardiovascular Homeostasis** **Krishna Singh,** *Western University London, Canada*
15:50-16:10	**Title: Prospective study of emergency medicine provider wellness across ten academic and community hospitals during the initial surge of the COVID-19 pandemic** **Kelker Heather,** *Riley Hospital for Children at Indiana Unversity Health, USA*
16:10-16:30	**Title: Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors** **Christina M. Dieli-Conwright,** *Harvard Medical School, USA*
16:30-16:50	**Combining PARP and FEN1/EXO1 inhibition in triple-negative breast cancer** **Saima Hassan,** *University of Montreal, Canada*
16:50-17:10	**Title: Rare Breast Cancers Review** **Harnoor Singh,** *University of Texas at Houston, USA*
17:10-17:30	**Title: Developing novel endocrine therapy controlling both estradiol and DHT against ER+ breast cancer** **Sheng-Xiang Lin,** *Centre de recherche du CHU et Université Laval, Canada*
17:30-17:50	**Title: Estimating the Lifetime Risk of Breast Cancer With and Without a Screening History** **Dongfeng Wu,** *University of Louisville, USA*
17:50-18:10	**Title: A novel method of finding non-infectious disease causes by combining multiple research and results of its application: A unique combination of physiological changes which causes Breast Cancer** **Alan Olan,** *Independent Researcher, USA*

18:10-18:30	**Title: Transgender breast imaging: current practice, challenges and future directions** **Jamie Spoont,** *University of Miami Miller School of Medicine, USA*
18:30-18:50	**Title: Molecular testing and targeting for solid tumors with CNS metastases** **Toni Cao,** *Stanford University School of Medicine, USA*
18:50-19:10	**Title: Leronlimab is associated with long-term survival in metastatic triple-negative breast cancer (mTNBC) potentially enhancing PD-L1 expression, and ICI response** **Richard G Pestell,** *The Baruch S Blumberg Institute, USA*
19:10-19:30	**Title: Recent progress on optical imaging for intraoperative assessment of tumor margins during lumpectomy** **Bing Yu,** *Marquette University and Medical College of Wisconsin, USA*
19:30-19:50	**Title: Quercetin targets TGFb-primed human MDA-MB-231 triple-negative breast cancer cells, linking epithelial-mesenchymal transition to cell senescence and fibrosis** **Borhane Annabi,** *Université du Québec à Montréal, Canada*
19:50-20:10	**Title: Integrated in vitro and in silico analysis of pomegranate-derived polyphenols targeting novel variants in MCF-7 breast cancer cells** **Anum Munir,** *Stanford University School of Medicine, USA*
Closing Ceremany	

Notes

Notes

Notes

WE WISH TO SEE YOU AGAIN AT

14th Global Insight Conference on

Breast Cancer

June 28-29, 2027 *at* Barcelona, Spain

Website URL: https://gicbc.org/ ***Email: breastcancer@innovinc.org***

INNOVINC INTERNATIONAL

USA: 5201 Great America Pkwy #320, Santa Clara, CA 95054, United States Ph: +1-408-465-0048